Axovant slates a New York Stock Exchange listing with a goal of raising $251M.The company bought its lead drug candidate from GlaxoSmithKline in December 2014 and hopes to take the treatment where Glaxo could not -- to effectiveness and to market. Stage 3 clinical trials are set for the end of 2015.
Axovant has ties to a hedge fund financier and the UK-based drug company Dexcel Pharma.
Sharron Silvers, a financial PR veteran and senior director at Burson, is advising Axovant.
Edelman handles Viking Holdings, the river and ocean luxury cruise line that plans to raise $1B via an IPO priced in the $21 to $25 per share range.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Tod Donhauser, a nine-year veteran of Edelman, has joined H/Advisors Abernathy as managing director and head of its San Francisco office.
Have a comment? Send it to 
No comments have been submitted for this story yet.